Shaheer Bardissi

Shaheer Bardissi serves as Co-CEO at Minapharm Pharmaceuticals since April 2020 and is also an executive board member focusing on cell and gene therapy as well as immuno-oncology. In addition, Shaheer is a member of the supervisory board at ProBioGen AG and co-founder of MiGenTra GmbH, where involvement includes advisory board membership and participation in the shareholder committee. As General Manager at Bardissi Medical, Shaheer specializes in immuno-oncology and cell therapy. Shaheer's past experience includes working in immuno-oncology technology development at BioNTech SE. Educational qualifications include a PhD in Cell & Gene therapy and personalized immuno-oncology from Johannes Gutenberg University Mainz, an MS in Quantitative Management Science with a focus on healthcare data analytics and artificial intelligence from Duke University's Fuqua School of Business, an MS in Molecular Medicine from UCL, and a BS in Biomedical Sciences from King's College London.